>I thought the significance of Kamada's orphan drug status was the aerosol delivery.<
It is. However, GTC hopes to eventually have its own inhaled AAT product and hence being able to break Kamada’s orphan status is relevant. From the 3Q07 CC (#msg-24216158):
“…our program in alpha 1-antitrypsin is continuing to move ahead steadily… The future may lie in the development of a pulmonary delivery of this product which, in turn, may open up the opportunity of a broader range of clinical indications in which elastase destruction of the lung and resulting inflammatory conditions play a part.”
News 
Market Data 
Discover 
